Skip to main content
SpringerLink
Log in

Amniotic membrane in dry-eye disease: better outcomes at lower cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by TissueTech.

Reference

  • Voigt J. Cost utility analysis of cryopreserved amniotic membrane versus topical cyclosporine for the treatment of moderate to severe dry eye syndrome. Cost Effectiveness and Resource Allocation : 1 Dec 2020. Available from: URL: https://doi.org/10.1186/s12962-020-00252-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amniotic membrane in dry-eye disease: better outcomes at lower cost. PharmacoEcon Outcomes News 868, 3 (2020). https://doi.org/10.1007/s40274-020-7335-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7335-y

Search

Navigation